Thursday, November 12, 2026

BMO Exit from AIR MILES Program Threatens $8M Annual Revenue Stream for Diversified Royalty Corp.

Bank of Montreal's departure from the AIR MILES Reward Program in 2026 will eliminate a significant revenue source for Diversified Royalty Corp., which owns the loyalty program through AM Royalties Limited Partnership. The bank serves as both major program participant and guarantor/financier of the partnership structure, making the transition particularly consequential for royalty income and dividend sustainability.

BMO Exit from AIR MILES Program Threatens $8M Annual Revenue Stream for Diversified Royalty Corp.
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Bank of Montreal confirmed its exit from the AIR MILES Reward Program effective 2026, creating immediate concerns for Diversified Royalty Corp.'s income stability. BMO holds dual roles as program participant and financial guarantor of AM Royalties Limited Partnership, amplifying the impact beyond typical partner departures.

Diversified Royalty Corp. derives royalty income from AIR MILES transactions through its ownership of AM Royalties Limited Partnership. BMO's withdrawal removes both transaction volume and structural financial support that underpins the royalty arrangement.

The company amended AIR MILES License Agreements on January 26, 2026, likely restructuring terms to address BMO's departure. These amendments suggest negotiations to minimize financial disruption, though specific terms remain undisclosed.

Analysts project BMO's exit could reduce Diversified Royalty's AIR MILES segment revenue by 15-20% based on the bank's estimated contribution to program activity. The company reported $42.3M in total royalty income for fiscal 2025, with AIR MILES representing approximately 35% of that figure.

Dividend sustainability faces scrutiny as Diversified Royalty maintains a monthly distribution of $0.02083 per share ($0.25 annually). The current payout ratio of 94% leaves minimal buffer for revenue declines. A 15% drop in AIR MILES royalties would push the payout ratio above 100%, forcing dividend cuts or asset sales.

The AIR MILES program has struggled with partner retention as Canadian banks develop proprietary rewards systems. TD Bank, CIBC, and Scotiabank now operate independent programs, preferring full control over customer data and rewards economics.

Diversified Royalty stock trades at $2.87 on the TSX, down 8% since BMO announced the transition. The company's enterprise value of $186M consists primarily of royalty stream valuations, making partner concentration risk acute.

Management has not provided updated 2026 guidance following the BMO announcement. Investors await Q1 2026 results in May to assess actual revenue impact and potential strategic responses, including acquisition of replacement royalty assets or program restructuring to retain remaining partners.

The broader shift toward proprietary loyalty programs among major banks suggests additional AIR MILES partners may reconsider participation, creating cascading risk for Diversified Royalty's long-term income profile.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com